IPX 231

Drug Profile

IPX 231

Alternative Names: IPX-231; IPX231-C0001; IPX231-L0007; IPX231-L0012

Latest Information Update: 15 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Impax Pharmaceuticals
  • Class Antiparkinsonians
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Parkinson's disease

Most Recent Events

  • 01 Aug 2014 IPX 231 is available for licensing as of 01 Aug 2014. http://www.impaxlabs.com/our_company/future_directions
  • 03 Jun 2014 Impax Pharmaceuticals completes a phase I trial in Parkinson's disease (in volunteers) in Australia (ACTRN12613001057774)
  • 28 Feb 2014 Phase-I clinical trials in Parkinson's disease (in volunteers) in Australia (Sublingual; liquid, powder)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top